tipiracil/trifluridine; TAS-102 (Lonsurf)
Jump to navigation
Jump to search
Indications
- treatment of metastatic colorectal adenocarcinoma[1]*
* improves life-expectancy 7.1 vs. 5.3 months in patients refractory to conventional therapy[1]
Contraindications
Pregnancy category: X :Safety in lactation: -
Monitor
- complete blood count (CBC) prior to each treatment
Adverse effects
- anemia
- neutropenia
- thrombocytopenia
- weakness
- fatigue
- anorexia
- nausea/vomiting
- diarrhea
- abdominal pain
- fever[2]
More general terms
Components
References
- ↑ 1.0 1.1 1.2 Mayer RJ et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 2015 May 14; 372:1909 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25970050 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1414325
- ↑ 2.0 2.1 FDA News Release. September 22, 2015 FDA approves new oral medication to treat patients with advanced colorectal cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm463650.htm